Endoscopic Retrograde Cholangiopancreatography
ConditionGastro-Intestinal Disorder
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15+
SponsorMethodist Health System
About this trial
The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients who underwent ERCP and in MDI(Methodist Digestive Institute) registry.
Trial design
Design model
Case-only
Time perspective
Other
Treatments tested in this trial
Patients undergoing ERCPs at Methodist Dallas Medical Center
Other interventionThe registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Underwent ERCP1 intervention
Trial outcomes
Primary outcomes
1
Underwent ERCP
Patients undergoing ERCPs at Methodist Dallas Medical Center.
Time frame
25 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov